Comparative Pharmacology
Head-to-head clinical analysis: BYSTOLIC versus SECTRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYSTOLIC versus SECTRAL.
BYSTOLIC vs SECTRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bystolic (nebivolol) is a beta-1 selective adrenergic receptor antagonist with additional nitric oxide-mediated vasodilatory effects. It decreases heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart and kidney, and enhances nitric oxide release from vascular endothelium via beta-3 receptor activation.
Selective beta-1 adrenergic receptor antagonist; negative chronotropic and inotropic effects, reduces cardiac output, decreases renin release.
Oral: 5 mg once daily; may increase at 2-week intervals to 10 mg, 20 mg, 40 mg; maximum 40 mg/day.
Adult: 200–400 mg orally once daily, initially; may increase to 400–800 mg daily in divided doses (e.g., 200 mg twice daily). Maximum 800 mg/day. Route: Oral.
None Documented
None Documented
Terminal elimination half-life: 10-12 hours; allows once-daily dosing in most patients; steady-state achieved in 3-5 days
Terminal elimination half-life: 8-13 hours; clinically, this supports once-daily dosing, but steady-state is achieved within 2-3 days.
Renal: 38% unchanged; hepatic metabolism: extensive; fecal: minor; total renal clearance accounts for 30-50% of dose
Renal: ~30-40% unchanged; biliary/fecal: ~20-30% as metabolites and parent compound; total renal clearance accounts for 50-70% of elimination.
Category C
Category C
Beta Blocker
Beta Blocker